8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Apr 6, 2026·SEC
Material company update
Mar 31, 2026·SEC
Biogen Inc.(BIIB)Earnings, Financials & Key Ratios
BIIB•NASDAQ
$189.13
$27.92B mkt cap·21.4× P/E·Price updated May 6, 2026
AboutBiogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$9.81B+1.4%
- EBITDA$2.81B-11.1%
- Net Income$1.29B-20.8%
- EPS (Diluted)8.83-21.1%
- Gross Margin70.47%-7.4%
- EBITDA Margin28.67%-12.3%
- Operating Margin19.14%-25.6%
- Net Margin13.18%-21.8%
- ROE7.4%-28.6%
- ROIC6.52%-26.5%
- Debt/Equity0.38-4.1%
- Interest Coverage8.80-5.1%
BIIB Key Insights
Biogen Inc. (BIIB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 20.9% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy 5Y average net margin of 17.2%
✗Weaknesses
- ✗Profits declining 20.2% over 5 years
- ✗Sales declining 6.1% over 5 years
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BIIB Price & Volume
Biogen Inc. (BIIB) stock price & volume — 10-year historical chart
Loading chart...
BIIB Growth Metrics
Biogen Inc. (BIIB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-0.92%
5 Years-6.11%
3 Years-1.2%
TTM0.42%
Profit CAGR
10 Years-9.6%
5 Years-20.22%
3 Years-24.85%
TTM-7.23%
EPS CAGR
10 Years-5.37%
5 Years-18.66%
3 Years-24.93%
TTM-7.8%
Return on Capital
10 Years19.2%
5 Years11.18%
3 Years9.32%
Last Year7.72%
BIIB Recent Earnings
Biogen Inc. (BIIB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
Apr 29, 2026EPS
$3.57
Est $3.05
+17.0%
Revenue
$2.5B
Est $2.3B
+8.4%
Q1 2026
Feb 6, 2026EPS
$1.99
Est $1.63
+22.1%
Revenue
$2.3B
Est $2.2B
+3.5%
Q4 2025
Oct 30, 2025EPS
$4.81
Est $3.88
+24.0%
Revenue
$2.5B
Est $2.3B
+4.9%
Q3 2025
Jul 31, 2025EPS
$5.47
Est $3.90
+40.3%
Revenue
$2.6B
Est $2.3B
+13.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $3.57vs $3.05+17.0% | $2.5Bvs $2.3B+8.4% |
| Q1 2026 | Feb 6, 2026 | $1.99vs $1.63+22.1% | $2.3Bvs $2.2B+3.5% |
| Q4 2025 | Oct 30, 2025 | $4.81vs $3.88+24.0% | $2.5Bvs $2.3B+4.9% |
| Q3 2025 | Jul 31, 2025 | $5.47vs $3.90+40.3% | $2.6Bvs $2.3B+13.6% |
Based on last 12 quarters of dataView full earnings history →
BIIB Peer Comparison
Biogen Inc. (BIIB) competitors in Specialty and biologics-focused pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 REGN | 72.97B | 702.33 | 16.93 | 0.99% | 29.65% | 14.32% | 5.59% | 0.09 |
 VRTX | 107.94B | 424.36 | 27.70 | 9.57% | 35.4% | 23.93% | 2.96% | 0.21 |
 BMRN | 10.24B | 53.24 | 29.58 | 12.87% | 8.29% | 4.41% | 7.08% | 0.11 |
 ALNY | 40.18B | 301.11 | 129.23 | 65.19% | 13.46% | 98.29% | 1.16% | 1.62 |
 GILD | 166.32B | 133.48 | 351.26 | 6.04% | 28.9% | 37.62% | 6.2% | 1.39 |
 AMGN | 177.87B | 329.59 | 23.16 | 9.92% | 20.95% | 89.41% | 4.55% | 6.31 |
 INCY | 19.47B | 97.47 | 15.21 | 21.22% | 26.71% | 29.31% | 6.96% | 0.01 |
 IONS | 12.44B | 75.25 | -31.62 | 33.87% | -30.87% | -58.57% | 5.35 |
Compare BIIB vs Peers
Biogen Inc. (BIIB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BIIB Income Statement
Biogen Inc. (BIIB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 12.27B | 13.45B | 14.38B | 13.44B | 10.98B | 10.17B | 9.84B | 9.68B | 9.81B | 9.86B |
| Revenue Growth % | 7.21% | 9.61% | 6.88% | -6.49% | -18.32% | -7.36% | -3.32% | -1.62% | 1.39% | 0.42% |
| Cost of Goods Sold | 1.63B | 1.82B | 1.96B | 1.81B | 2.11B | 2.28B | 2.53B | 2.31B | 2.9B | 2.98B |
| COGS % of Revenue | 13.28% | 13.5% | 13.6% | 13.43% | 19.21% | 22.39% | 25.76% | 23.88% | 29.53% | - |
| Gross Profit | 10.64B▲ 0% | 11.64B▲ 9.3% | 12.42B▲ 6.8% | 11.64B▼ 6.3% | 8.87B▼ 23.8% | 7.9B▼ 11.0% | 7.3B▼ 7.5% | 7.37B▲ 0.9% | 6.91B▼ 6.1% | 6.88B▲ 0% |
| Gross Margin % | 86.72% | 86.5% | 86.4% | 86.57% | 80.79% | 77.61% | 74.24% | 76.12% | 70.47% | 69.77% |
| Gross Profit Growth % | 6.27% | 9.33% | 6.75% | -6.3% | -23.78% | -11.01% | -7.51% | 0.87% | -6.14% | - |
| Operating Expenses | 5.3B | 5.75B | 5.38B | 7.05B | 6.08B | 5.01B | 5.2B | 4.88B | 5.04B | 5.33B |
| OpEx % of Revenue | 43.17% | 42.73% | 37.42% | 52.41% | 55.37% | 49.21% | 52.92% | 50.39% | 51.33% | - |
| Selling, General & Admin | 1.94B | 2.11B | 2.36B | 2.52B | 2.68B | 2.41B | 2.5B | 2.39B | 2.43B | 2.47B |
| SG&A % of Revenue | 15.78% | 15.68% | 16.41% | 18.71% | 24.41% | 23.68% | 25.44% | 24.67% | 24.81% | - |
| Research & Development | 2.37B | 2.71B | 2.77B | 4.53B | 3.4B | 2.6B | 2.7B | 2.49B | 1.95B | 1.98B |
| R&D % of Revenue | 19.34% | 20.14% | 19.27% | 33.7% | 30.97% | 25.53% | 27.48% | 25.72% | 19.92% | - |
| Other Operating Expenses | 988.1M | 929.2M | 250.5M | 0 | 0 | 0 | 0 | 0 | 647.7M | 2M |
| Operating Income | 5.35B▲ 0% | 5.89B▲ 10.2% | 7.04B▲ 19.6% | 4.59B▼ 34.8% | 2.79B▼ 39.2% | 2.89B▲ 3.5% | 2.1B▼ 27.4% | 2.49B▲ 18.7% | 1.88B▼ 24.6% | 1.54B▲ 0% |
| Operating Margin % | 43.55% | 43.77% | 48.98% | 34.16% | 25.42% | 28.4% | 21.32% | 25.74% | 19.14% | 15.65% |
| Operating Income Growth % | 3.77% | 10.15% | 19.6% | -34.78% | -39.22% | 3.5% | -27.41% | 18.74% | -24.61% | - |
| EBITDA | 6.07B | 6.54B | 7.51B | 5.05B | 3.28B | 3.41B | 2.59B | 3.16B | 2.81B | 2.43B |
| EBITDA Margin % | 49.43% | 48.61% | 52.21% | 37.56% | 29.86% | 33.49% | 26.35% | 32.69% | 28.67% | 24.66% |
| EBITDA Growth % | 4.81% | 7.77% | 14.81% | -32.73% | -35.07% | 3.92% | -23.93% | 22.04% | -11.08% | -16% |
| D&A (Non-Cash Add-back) | 721.6M | 650.5M | 464.7M | 457.2M | 487.7M | 518.4M | 494.8M | 673.2M | 935.4M | 888.7M |
| EBIT | 5.89B | 6.36B | 7.28B | 4.65B | 3.44B | 3.02B | 1.88B | 2.32B | 2.17B | 1.9B |
| Net Interest Income | -172.3M | -88.1M | -67.4M | -180.5M | -242.6M | -157.3M | 29.6M | -182.7M | -158.2M | -136.1M |
| Interest Income | 78.5M | 112.5M | 120M | 42M | 11M | 89.3M | 276.5M | 67.6M | 87.8M | 139M |
| Interest Expense | 250.8M | 200.6M | 187.4M | 222.5M | 253.6M | 246.6M | 246.9M | 250.3M | 246M | 275.1M |
| Other Income/Expense | -217M | 11M | 3.9M | 459.8M | -1.01B | 705.3M | -800.5M | -584.3M | -476M | -74.3M |
| Pretax Income | 5.13B▲ 0% | 5.9B▲ 15.0% | 7.05B▲ 19.4% | 5.05B▼ 28.3% | 1.78B▼ 64.8% | 3.59B▲ 101.9% | 1.3B▼ 63.9% | 1.91B▲ 47.0% | 1.4B▼ 26.5% | 1.47B▲ 0% |
| Pretax Margin % | 41.79% | 43.85% | 49.01% | 37.58% | 16.21% | 35.33% | 13.18% | 19.7% | 14.29% | 14.89% |
| Income Tax | 2.46B | 1.43B | 1.16B | 992.3M | 52.5M | 632.8M | 135.3M | 273.8M | 108.11M | 95.61M |
| Effective Tax Rate % | 47.94% | 24.16% | 16.43% | 19.64% | 2.95% | 17.61% | 10.43% | 14.37% | 7.71% | 6.51% |
| Net Income | 2.54B▲ 0% | 4.43B▲ 74.5% | 5.89B▲ 32.9% | 4B▼ 32.1% | 1.56B▼ 61.1% | 3.05B▲ 95.8% | 1.16B▼ 61.9% | 1.63B▲ 40.6% | 1.29B▼ 20.8% | 1.37B▲ 0% |
| Net Margin % | 20.69% | 32.93% | 40.96% | 29.76% | 14.17% | 29.95% | 11.81% | 16.87% | 13.18% | 13.92% |
| Net Income Growth % | -31.43% | 74.5% | 32.9% | -32.06% | -61.1% | 95.8% | -61.89% | 40.57% | -20.76% | -7.23% |
| Net Income (Continuing) | 2.67B | 4.47B | 5.89B | 4.06B | 1.73B | 2.96B | 1.16B | 1.63B | 1.29B | 1.37B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -14.7M | -8M | -4.1M | -14.2M | 63.5M | -9.5M | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 11.92▲ 0% | 21.58▲ 81.0% | 31.42▲ 45.6% | 24.80▼ 21.1% | 10.40▼ 58.1% | 20.87▲ 100.7% | 7.97▼ 61.8% | 11.19▲ 40.4% | 8.83▼ 21.1% | 9.25▲ 0% |
| EPS Growth % | -29.59% | 81.04% | 45.6% | -21.07% | -58.06% | 100.67% | -61.81% | 40.4% | -21.09% | -7.8% |
| EPS (Basic) | 11.94 | 21.62 | 31.47 | 24.86 | 10.44 | 20.97 | 8.02 | 11.20 | 8.85 | - |
| Diluted Shares Outstanding | 213M | 205.3M | 187.4M | 161.3M | 149.6M | 146M | 145.6M | 145.9M | 146.7M | 148.4M |
| Basic Shares Outstanding | 212.6M | 204.9M | 187.1M | 160.9M | 149.1M | 145.3M | 144.7M | 145.7M | 146.7M | 147.2M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BIIB Balance Sheet
Biogen Inc. (BIIB) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 7.87B | 7.64B | 8.38B | 6.89B | 7.86B | 9.79B | 6.86B | 7.46B | 8.97B | 9.19B |
| Cash & Short-Term Investments | 3.69B | 3.54B | 4.48B | 2.61B | 3.8B | 4.89B | 1.05B | 2.38B | 3.82B | 4.28B |
| Cash Only | 1.57B | 1.22B | 2.91B | 1.33B | 2.26B | 3.42B | 1.05B | 2.38B | 3.01B | 3.38B |
| Short-Term Investments | 2.12B | 2.31B | 1.56B | 1.28B | 1.54B | 1.47B | 0 | 0 | 807.2M | 900M |
| Accounts Receivable | 2.32B | 2.49B | 2.47B | 2.33B | 1.96B | 2.14B | 2.1B | 1.87B | 1.87B | 1.79B |
| Days Sales Outstanding | 68.98 | 67.43 | 62.72 | 63.18 | 65.2 | 76.65 | 77.93 | 70.5 | 69.46 | 70.27 |
| Inventory | 902.7M | 929.9M | 804.2M | 1.07B | 1.35B | 1.34B | 2.53B | 2.46B | 2.17B | 1.95B |
| Days Inventory Outstanding | 202.14 | 186.87 | 150.11 | 216.06 | 233.82 | 215.38 | 364.14 | 388.71 | 273.16 | 263.35 |
| Other Current Assets | 304.4M | 687.6M | 631M | 881.1M | 740.8M | 1.42B | 1.18B | 752.5M | 1.12B | 1.17B |
| Total Non-Current Assets | 15.78B | 17.65B | 18.85B | 17.73B | 16.02B | 14.76B | 19.99B | 20.59B | 20.47B | 20.29B |
| Property, Plant & Equipment | 3.18B | 3.6B | 3.67B | 3.84B | 3.79B | 3.7B | 3.73B | 3.54B | 3.32B | 3.27B |
| Fixed Asset Turnover | 3.86x | 3.74x | 3.91x | 3.50x | 2.90x | 2.75x | 2.64x | 2.74x | 2.95x | 2.94x |
| Goodwill | 4.63B | 5.71B | 5.76B | 5.76B | 5.76B | 5.75B | 6.22B | 6.48B | 6.49B | 6.49B |
| Intangible Assets | 3.88B | 3.12B | 3.53B | 3.08B | 2.22B | 1.85B | 8.36B | 9.69B | 9.18B | 9.05B |
| Long-Term Investments | 3.06B | 1.38B | 1.41B | 772.1M | 892M | 705.7M | 0 | 226.7M | 750.6M | 2.17B |
| Other Non-Current Assets | 431.6M | 1.69B | 1.25B | 2.9B | 1.94B | 1.53B | 745M | 333.8M | 431.9M | 1.62B |
| Total Assets | 23.65B▲ 0% | 25.29B▲ 6.9% | 27.23B▲ 7.7% | 24.62B▼ 9.6% | 23.88B▼ 3.0% | 24.55B▲ 2.8% | 26.84B▲ 9.3% | 28.05B▲ 4.5% | 29.44B▲ 5.0% | 29.48B▲ 0% |
| Asset Turnover | 0.52x | 0.53x | 0.53x | 0.55x | 0.46x | 0.41x | 0.37x | 0.34x | 0.33x | 0.34x |
| Asset Growth % | 3.39% | 6.92% | 7.69% | -9.6% | -3.01% | 2.83% | 9.33% | 4.49% | 4.96% | 18.98% |
| Total Current Liabilities | 3.37B | 3.3B | 4.86B | 3.74B | 4.3B | 3.27B | 3.43B | 5.53B | 3.35B | 3B |
| Accounts Payable | 395.5M | 370.5M | 530.8M | 454.9M | 589.2M | 491.5M | 403.3M | 424.2M | 432M | 358.5M |
| Days Payables Outstanding | 88.56 | 74.45 | 99.08 | 91.98 | 101.94 | 78.74 | 58.11 | 67.02 | 54.43 | 49.36 |
| Short-Term Debt | 3.2M | 0 | 1.5B | 0 | 999.1M | 0 | 150M | 1.75B | 80.4M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 297.7M | 320.9M | 315.8M | 515.3M | 345.1M | 1.14B | 335.1M | 375.8M | 2.72B | 192.5M |
| Current Ratio | 2.34x | 2.32x | 1.72x | 1.84x | 1.83x | 2.99x | 2.00x | 1.35x | 2.68x | 2.68x |
| Quick Ratio | 2.07x | 2.04x | 1.56x | 1.55x | 1.51x | 2.58x | 1.26x | 0.90x | 2.03x | 2.03x |
| Cash Conversion Cycle | 182.56 | 179.85 | 113.76 | 187.27 | 197.09 | 213.29 | 383.96 | 392.19 | 288.2 | 284.27 |
| Total Non-Current Liabilities | 7.69B | 8.96B | 9.03B | 10.19B | 8.62B | 7.89B | 8.61B | 5.8B | 7.83B | 7.83B |
| Long-Term Debt | 5.93B | 5.94B | 4.46B | 7.43B | 6.27B | 6.28B | 6.79B | 4.55B | 6.58B | 6.29B |
| Capital Lease Obligations | 0 | 0 | 412.7M | 402M | 330.4M | 333M | 400M | 334.5M | 290.4M | 1.18B |
| Deferred Tax Liabilities | 122.6M | 1.64B | 2.81B | 1.03B | 694.5M | 334.7M | 641.8M | 190.5M | 507.6M | 1.47B |
| Other Non-Current Liabilities | 1.63B | 1.39B | 1.35B | 1.33B | 1.32B | 944.2M | 781.1M | 732.3M | 458.1M | 2.81B |
| Total Liabilities | 11.05B | 12.26B | 13.9B | 13.93B | 12.92B | 11.17B | 12.05B | 11.33B | 11.18B | 10.83B |
| Total Debt | 5.94B | 5.94B | 6.37B | 7.83B | 7.6B | 6.61B | 7.34B | 6.63B | 6.95B | 6.56B |
| Net Debt | 4.36B | 4.71B | 3.45B | 6.5B | 5.34B | 3.19B | 6.29B | 4.26B | 3.94B | 3.18B |
| Debt / Equity | 0.47x | 0.46x | 0.48x | 0.73x | 0.69x | 0.49x | 0.50x | 0.40x | 0.38x | 0.38x |
| Debt / EBITDA | 0.98x | 0.91x | 0.85x | 1.55x | 2.32x | 1.94x | 2.83x | 2.10x | 2.47x | 2.70x |
| Net Debt / EBITDA | 0.72x | 0.72x | 0.46x | 1.29x | 1.63x | 0.94x | 2.43x | 1.35x | 1.40x | 1.40x |
| Interest Coverage | 23.47x | 31.73x | 38.82x | 20.90x | 13.55x | 12.24x | 7.62x | 9.28x | 8.80x | 6.91x |
| Total Equity | 12.6B▲ 0% | 13.03B▲ 3.4% | 13.34B▲ 2.3% | 10.69B▼ 19.9% | 10.96B▲ 2.6% | 13.39B▲ 22.2% | 14.8B▲ 10.5% | 16.72B▲ 13.0% | 18.26B▲ 9.2% | 18.65B▲ 0% |
| Equity Growth % | 3.87% | 3.44% | 2.33% | -19.86% | 2.56% | 22.16% | 10.54% | 12.95% | 9.22% | 41.35% |
| Book Value per Share | 59.15 | 63.48 | 71.16 | 66.25 | 73.26 | 91.70 | 101.64 | 114.57 | 124.45 | 125.69 |
| Total Shareholders' Equity | 12.61B | 13.04B | 13.34B | 10.7B | 10.9B | 13.4B | 14.8B | 16.72B | 18.26B | 18.65B |
| Common Stock | 100K | 100K | 100K | 100K | 100K | 100K | 100K | 100K | 100K | 100K |
| Retained Earnings | 15.81B | 16.26B | 16.46B | 13.98B | 13.91B | 16.47B | 17.63B | 19.26B | 20.55B | 20.87B |
| Treasury Stock | -2.98B | -2.98B | -2.98B | -2.98B | -2.98B | -2.98B | -2.98B | -2.98B | -2.98B | -2.98B |
| Accumulated OCI | -318.4M | -240.4M | -135.2M | -299M | -106.7M | -164.9M | -153.7M | -136.2M | -182M | -140.2M |
| Minority Interest | -14.7M | -8M | -4.1M | -14.2M | 63.5M | -9.5M | 0 | 0 | 0 | 0 |
BIIB Cash Flow Statement
Biogen Inc. (BIIB) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 4.55B | 6.19B | 7.08B | 4.23B | 3.64B | 1.38B | 1.55B | 2.88B | 2.2B | 2.2B |
| Operating CF Margin % | 37.08% | 46% | 49.23% | 31.46% | 33.15% | 13.61% | 15.73% | 29.72% | 22.47% | - |
| Operating CF Growth % | 0.63% | 35.96% | 14.4% | -40.25% | -13.95% | -61.97% | 11.77% | 85.85% | -23.33% | 77.94% |
| Net Income | 2.67B | 4.47B | 5.89B | 4.06B | 1.73B | 2.96B | 1.16B | 1.63B | 1.29B | 1.37B |
| Depreciation & Amortization | 1.08B | 650.5M | 464.6M | 457.2M | 487.7M | 518.4M | 494.8M | 673.2M | 779.9M | 801.1M |
| Stock-Based Compensation | 128M | 157.5M | 182.3M | 198.3M | 238.6M | 254.1M | 264.2M | 291.2M | 290.8M | 293.8M |
| Deferred Taxes | 91.7M | 108.3M | 67.1M | 149M | -426.8M | -168.6M | -305.8M | -158.1M | 361.6M | 413M |
| Other Non-Cash Items | 344.8M | 397.2M | 276.7M | -448M | 1.76B | -1.29B | 581.2M | 592.2M | 537M | 563M |
| Working Capital Changes | 235.4M | 400.2M | 199.3M | -187.2M | -145.5M | -890.3M | -648.7M | -155.2M | -1.06B | -852M |
| Change in Receivables | -667.6M | -199.5M | 5.5M | 179.5M | 326M | -222.4M | 56.7M | 194.2M | 42.1M | 222.4M |
| Change in Inventory | -94.5M | -52.1M | -19.2M | -316.3M | -462.4M | -320.2M | -130.9M | -273.8M | -64.7M | -10.5M |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -2.96B | -2.05B | 470.5M | -608.6M | -563.7M | 1.59B | -4.09B | -799.2M | -1.37B | -1.53B |
| Capital Expenditures | -1.96B | -886.1M | -669.5M | -551.8M | -294.9M | -243.2M | -311.4M | -359.8M | -153.8M | -85.4M |
| CapEx % of Revenue | 15.99% | 6.59% | 4.66% | 4.1% | 2.69% | 2.39% | 3.17% | 3.72% | 1.57% | - |
| Acquisitions | 0 | 0 | 179.3M | 0 | 28.1M | 595M | -6.91B | -1.07B | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -1.21B | -1.5B | -273M | -26.9M | 12.9M | 24.4M | -11.3M | 83.9M | -38.7M | -1.29B |
| Cash from Financing | -2.38B | -4.47B | -5.86B | -5.27B | -2.09B | -1.76B | 137M | -683.5M | -301.9M | -322.6M |
| Debt Issued (Net) | -560.9M | -3.2M | 0 | 1.47B | -170M | -1B | 187.3M | -650M | -16.9M | -16.9M |
| Equity Issued (Net) | -1.37B | -4.35B | -5.87B | -6.68B | -1.8B | -751.9M | -44.3M | -31.3M | -10M | -40.8M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -1.37B | -4.35B | -5.87B | -6.68B | -1.8B | -750M | 0 | 0 | 0 | 0 |
| Other Financing | -453.7M | -116.2M | 7.9M | -56.4M | -115.5M | -5.6M | -6M | -2.2M | -275M | -264.9M |
| Net Change in Cash | -752.7M▲ 0% | -349.2M▲ 53.6% | 1.69B▲ 583.7% | -1.58B▼ 193.7% | 930.2M▲ 158.8% | 1.16B▲ 24.5% | -2.37B▼ 304.6% | 1.33B▲ 155.9% | 633.5M▼ 52.2% | 782.1M▲ 0% |
| Free Cash Flow | 3.68B▲ 0% | 5.3B▲ 43.9% | 6.56B▲ 23.8% | 3.81B▼ 42.0% | 3.38B▼ 11.1% | 1.14B▼ 66.2% | 1.24B▲ 8.0% | 2.52B▲ 103.6% | 2.05B▼ 18.5% | 2.62B▲ 0% |
| FCF Margin % | 30.01% | 39.41% | 45.65% | 28.3% | 30.79% | 11.24% | 12.56% | 26% | 20.9% | 26.61% |
| FCF Growth % | -4.56% | 43.92% | 23.81% | -42.03% | -11.12% | -66.17% | 8.02% | 103.57% | -18.48% | 14.27% |
| FCF per Share | 17.29 | 25.82 | 35.03 | 23.59 | 22.61 | 7.84 | 8.49 | 17.24 | 13.98 | 13.98 |
| FCF Conversion (FCF/Net Income) | 1.79x | 1.40x | 1.20x | 1.06x | 2.34x | 0.45x | 1.33x | 1.76x | 1.70x | 1.91x |
| Interest Paid | 0 | 0 | 0 | 272.7M | 280.8M | 262.5M | 252.2M | 245.4M | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 906.7M | 247.9M | 932.9M | 740.7M | 355.1M | 0 | 0 |
BIIB Key Ratios
Biogen Inc. (BIIB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 20.54% | 34.57% | 44.67% | 33.31% | 14.38% | 25.03% | 8.24% | 10.36% | 7.4% | 7.55% |
| Return on Invested Capital (ROIC) | 24.09% | 25.45% | 30.59% | 20.28% | 12.5% | 13.18% | 8.35% | 8.88% | 6.52% | 6.52% |
| Gross Margin | 86.72% | 86.5% | 86.4% | 86.57% | 80.79% | 77.61% | 74.24% | 76.12% | 70.47% | 69.77% |
| Net Margin | 20.69% | 32.93% | 40.96% | 29.76% | 14.17% | 29.95% | 11.81% | 16.87% | 13.18% | 13.92% |
| Debt / Equity | 0.47x | 0.46x | 0.48x | 0.73x | 0.69x | 0.49x | 0.50x | 0.40x | 0.38x | 0.38x |
| Interest Coverage | 23.47x | 31.73x | 38.82x | 20.90x | 13.55x | 12.24x | 7.62x | 9.28x | 8.80x | 6.91x |
| FCF Conversion | 1.79x | 1.40x | 1.20x | 1.06x | 2.34x | 0.45x | 1.33x | 1.76x | 1.70x | 1.91x |
| Revenue Growth | 7.21% | 9.61% | 6.88% | -6.49% | -18.32% | -7.36% | -3.32% | -1.62% | 1.39% | 0.42% |
BIIB SEC Filings & Documents
Biogen Inc. (BIIB) SEC filings — annual & quarterly reports (10-K, 10-Q)
BIIB Frequently Asked Questions
Biogen Inc. (BIIB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Biogen Inc. (BIIB) reported $9.86B in revenue for fiscal year 2025. This represents a 3457% increase from $277.1M in 1996.
Biogen Inc. (BIIB) grew revenue by 1.4% over the past year. Growth has been modest.
Yes, Biogen Inc. (BIIB) is profitable, generating $1.37B in net income for fiscal year 2025 (13.2% net margin).
Dividend & Returns
Biogen Inc. (BIIB) has a return on equity (ROE) of 7.4%. This is below average, suggesting room for improvement.
Biogen Inc. (BIIB) generated $2.62B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More BIIB
Biogen Inc. (BIIB) financial analysis — history, returns, DCA and operating performance tools
Full BIIB Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates